RestructuringJun 29, 2026, 07:01 AM
BioCryst Restructures R&D, Improves 2026 OpEx Guidance to $420-$440M
AI Summary
BioCryst Pharmaceuticals announced a strategic shift to prioritize external innovation, discontinuing internal discovery programs and closing its Birmingham Discovery Center by the end of 2026. This restructuring is expected to improve efficiency and lower costs, leading to an updated 2026 non-GAAP operating expense guidance of $420-$440 million, down from $450-$470 million. The company reaffirmed its 2026 revenue guidance and provided positive updates on its clinical pipeline, including completed enrollment for navenibart's Phase 3 study and resolved manufacturing delays for ORLADEYO oral pellets.
Key Highlights
- Discontinuing internal discovery programs and closing Birmingham Discovery Center by end of 2026.
- Improving 2026 non-GAAP operating expense guidance from $450-$470 million to $420-$440 million.
- Reaffirming full year 2026 ORLADEYO and total company revenue guidance.
- Navenibart Phase 3 ALPHA-ORBIT enrollment completed; top-line data expected Q3 2027.
- BCX17725 Phase 1 Part 4 dosing ongoing; proof-of-concept data expected by year-end 2026.
- Resolved ORLADEYO oral pellets manufacturing delay; product available early August 2026.
Price Impact
More from BCRX